References
- Pica F, Volpi A. Public awareness and knowledge of herpes labialis. J Med Virol 2012;84(1):132-7
- Bolognia JL, Jorizzo JL, Schaffer JV. Dermatology. Elsevier Saunders, Philadelphia, PA, USA; 2012
- Freeman ML, Sheridan BS, Bonneau RH, Hendricks RL. Psychological stress compromises CD8+ T cell control of latent herpes simplex virus type 1 infections. J Immunol 2007;179(1):322-8
- Young SK, Rowe NH, Buchanan RA. A clinical study for the control of facial mucocutaneous herpes virus infections. I. Characterization of natural history in a professional school population. Oral Surg Oral Med Oral Pathol 1976;41(4):498-507
- Wong YJ, Veitz-Keenan A. Systemic nucleoside antiviral agents may be effective in prevention of recurrent herpes labialis. Evid Based Dent 2013;14(2):54
- Cunningham A, Griffiths P, Leone P, et al. Current management and recommendations for access to antiviral therapy of herpes labialis. J Clin Virol 2012;53(1):6-11
- de Paula Eduardo C, Aranha AC, Simões A, et al. Laser treatment of recurrent herpes labialis: a literature review. Lasers Med Sci 2013. [Epub ahead of print]
- Rahimi H, Mara T, Costella J, et al. Effectiveness of antiviral agents for the prevention of recurrent herpes labialis: a systematic review and meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113(5):618-27
- El Hayderi L, Delvenne P, Rompen E, et al. Herpes simplex virus reactivation and dental procedures. Clin Oral Investig 2013;17(8):1961-4
- Hull CM, Brunton S. The role of topical 5% acyclovir and 1% hydrocortisone cream (Xerese) in the treatment of recurrent herpes simplex labialis. Postgrad Med 2010;122(5):1-6
- Tsambaos D, Rodi M, Pasmatzi E, et al. Long-term remission of recurrent herpes labialis following topical imiquimod application on distant healthy skin: a clinical and immunological study. Antivir Ther 2011;16(6):863-9
- Skulason S, Holbrook WP, Thormar H, et al. A study of the clinical activity of a gel combining monocaprin and doxycycline: a novel treatment for herpes labialis. J Oral Pathol Med 2012;41(1):61-7
- De Clercq E, Field HJ. Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006;147(1):1-11
- Bacon TH, Levin MJ, Leary JJ, et al. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003;16(1):114-28
- Morfin F, Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003;26(1):29-37
- Sitavig®. Summary of product characteristics. BioAlliance Pharma; 2013. p. 1-5
- Spruance SL, Overall JC Jr, Kern ER, et al. The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. N Engl J Med 1977;297(2):69-75
- Attali P. Pharmacokinetics, pharmacodynamics, safety, and tolerability of acyclovir Lauriad™ muco-adhesive buccal tablet in healthy volunteer subjects. Spring Symposium of the European Academy of Dermatology and Venereology 2013; 2013
- Dreno B, Malkin JE, Saiag P. Understanding recurrent herpes labialis management and impact on patients' quality of life: the HERPESCOPE study. Eur J Dermatol 2013;23(4):491-9
- Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med 2008;168(11):1137-44
- Gilbert SC. Management and prevention of recurrent herpes labialis in immunocompetent patients. Herpes 2007;14(3):56-61
- Feldman SJ, Rodman B. Gregory, Excessive serum concentrations of acyclovir and neurotoxicity. J Infect Dis 1988;157(2):385-8
- Vere Hodge RA, Field HJ. Antiviral agents for herpes simplex virus. Adv Pharmacol 2013;67:1-38
- Treister NS, Woo SB. Topical n-docosanol for management of recurrent herpes labialis. Expert Opin Pharmacother 2010;11(5):853-60